The vaccine has been approved for people aged 4 to 60 years and is administered as two doses, given three months apart. Notably, it requires no pre-vaccination screening, meaning people who have previously had dengue can also receive it without first being tested for past infection — a practical advantage in a country where dengue exposure is widespread and testing infrastructure is uneven.